The content on this site is intended for healthcare professionals only
Prof Michael Lübbert presents data from the open-label randomised phase III study of the EORTC Leukemia group, GIMEMA, CELG, and GMDS- SG trial during a press conference at the EHA 2022 meeting.
The study compared the efficacy and safety of 10-day decitabine with conventional 3+7 IC as a treatment before HSCT in older (≥60 years) patients with newly diagnosed AML.
Read our news story here
30 minute infusion of isatuximab shows potential in newly diagnosed multiple myeloma
Understanding the remaining unmet needs in a post ASCT NDMM setting
ATRA-ATO regimen with idarubicin could become the new standard of care in high-risk acute promyelocytic leukaemia
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment
Triplets for newly diagnosed unfit AML patients could be feasible with substantial venetoclax reduction
Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL
